Targeting TNFR2 in Cancer: All Roads Lead to Rome

TNF receptor 2 (TNFR2) has become one of the best potential immune checkpoints that might be targeted, mainly because of its vital role in tumor microenvironments (TMEs). Overexpression of TNFR2 in some tumor cells and essential function in immunosuppressive cells, especially regulatory T cells (Tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Jingchao, Ding, Bowen, Li, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891135/
https://www.ncbi.nlm.nih.gov/pubmed/35251045
http://dx.doi.org/10.3389/fimmu.2022.844931
_version_ 1784661803257561088
author Bai, Jingchao
Ding, Bowen
Li, Hui
author_facet Bai, Jingchao
Ding, Bowen
Li, Hui
author_sort Bai, Jingchao
collection PubMed
description TNF receptor 2 (TNFR2) has become one of the best potential immune checkpoints that might be targeted, mainly because of its vital role in tumor microenvironments (TMEs). Overexpression of TNFR2 in some tumor cells and essential function in immunosuppressive cells, especially regulatory T cells (Tregs), makes blocking TNFR2 an excellent strategy in cancer treatment; however, there is evidence showing that activating TNFR2 can also inhibit tumor progression in vivo. In this review, we will discuss drugs that block and activate TNFR2 under clinical trials or preclinical developments up till now. Meanwhile, we summarize and explore the possible mechanisms related to them.
format Online
Article
Text
id pubmed-8891135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88911352022-03-04 Targeting TNFR2 in Cancer: All Roads Lead to Rome Bai, Jingchao Ding, Bowen Li, Hui Front Immunol Immunology TNF receptor 2 (TNFR2) has become one of the best potential immune checkpoints that might be targeted, mainly because of its vital role in tumor microenvironments (TMEs). Overexpression of TNFR2 in some tumor cells and essential function in immunosuppressive cells, especially regulatory T cells (Tregs), makes blocking TNFR2 an excellent strategy in cancer treatment; however, there is evidence showing that activating TNFR2 can also inhibit tumor progression in vivo. In this review, we will discuss drugs that block and activate TNFR2 under clinical trials or preclinical developments up till now. Meanwhile, we summarize and explore the possible mechanisms related to them. Frontiers Media S.A. 2022-02-17 /pmc/articles/PMC8891135/ /pubmed/35251045 http://dx.doi.org/10.3389/fimmu.2022.844931 Text en Copyright © 2022 Bai, Ding and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bai, Jingchao
Ding, Bowen
Li, Hui
Targeting TNFR2 in Cancer: All Roads Lead to Rome
title Targeting TNFR2 in Cancer: All Roads Lead to Rome
title_full Targeting TNFR2 in Cancer: All Roads Lead to Rome
title_fullStr Targeting TNFR2 in Cancer: All Roads Lead to Rome
title_full_unstemmed Targeting TNFR2 in Cancer: All Roads Lead to Rome
title_short Targeting TNFR2 in Cancer: All Roads Lead to Rome
title_sort targeting tnfr2 in cancer: all roads lead to rome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891135/
https://www.ncbi.nlm.nih.gov/pubmed/35251045
http://dx.doi.org/10.3389/fimmu.2022.844931
work_keys_str_mv AT baijingchao targetingtnfr2incancerallroadsleadtorome
AT dingbowen targetingtnfr2incancerallroadsleadtorome
AT lihui targetingtnfr2incancerallroadsleadtorome

Ejemplares similares